HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression

Epigenetic therapy inhibits metastases by disrupting premetastatic niches

(2020) Zhihao Lu et al.   NATURE

Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression

(2020) Zhiqi Xie et al.   OncoImmunology

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

(2020) Johannes Laengle et al.   Journal for ImmunoTherapy of Cancer

Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment

(2019) Huizhong Xiong et al.   CANCER RESEARCH

The emerging role of epigenetic therapeutics in immuno-oncology

(2019) Michael J. Topper et al.   Nature Reviews Clinical Oncology

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

(2019) Daphné Morel et al.   Nature Reviews Clinical Oncology

Harnessing innate immunity in cancer therapy

(2019) Olivier Demaria et al.   NATURE

Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis

(2019) Shu-Nan Cui et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Harnessing tumor-associated macrophages as aids for cancer immunotherapy

(2019) Xiaolei Li et al.   Molecular Cancer

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

(2019) Joseph A. Flores-Toro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

(2018) Xiaolei Li et al.   Cellular & Molecular Immunology

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants

(2018) Andrew Nguyen et al.   Cell Reports

The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy

(2018) Helen Loo Yau et al.   TRENDS IN CELL BIOLOGY

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

Chromatin states define tumour-specific T cell dysfunction and reprogramming

(2017) Mary Philip et al.   NATURE

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis

(2016) Ido Amit et al.   NATURE IMMUNOLOGY

Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer

(2015) N. Gul et al.   CANCER RESEARCH

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

(2015) Nicholas Butowski et al.   NEURO-ONCOLOGY

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

(2015) K Cao et al.   ONCOGENE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

(2014) Nuray Gül et al.   JOURNAL OF CLINICAL INVESTIGATION

The cellular and molecular origin of tumor-associated macrophages

(2014) R. A. Franklin et al.   SCIENCE

Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity

(2014) S. Saeed et al.   SCIENCE

Interleukin-4- and Interleukin-13-Mediated Alternatively Activated Macrophages: Roles in Homeostasis and Disease

(2013) Steven J. Van Dyken et al.   Annual Review of Immunology

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

(2013) Y Ino et al.   BRITISH JOURNAL OF CANCER

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

(2013) Felix Klug et al.   CANCER CELL

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

The future of epigenetic therapy in solid tumours—lessons from the past

(2013) Nilofer Azad et al.   Nature Reviews Clinical Oncology

The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients

(2012) Catharina Medrek et al.   BMC CANCER

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS

(2010) Maria A. Halili et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Leukocytes in Mammary Development and Cancer

(2010) L. M. Coussens et al.   Cold Spring Harbor Perspectives in Biology

A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships

(2009) F. Pucci et al.   BLOOD